文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

莫西沙星对生殖支原体感染疗效下降:需氟喹诺酮耐药指导治疗?

Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance-Guided Therapy?
PubMed 文献 · J Infect Dis · 2026-01-01

墨尔本性健康中心2015-2024年数据显示,生殖支原体感染中莫西沙星使用比例从6.7%升至60.3%(2023年),疗效从100%(2015年)降至79.3%(2023年)。2024年引入ParC-S83检测后,莫西沙星使用降至49.2%,野生型感染治愈率升至89.2%。

要点

  • 莫西沙星对生殖支原体疗效十年间显著下降,与耐药上升相关。
  • ParC-S83检测可指导用药,减少莫西沙星使用并提高治愈率。
  • 临床应关注氟喹诺酮耐药,考虑耐药指导治疗策略。

核心结论

  • 莫西沙星使用增加而疗效下降反映该地区生殖支原体耐药上升。
  • 初步数据提示ParC-S83检测可能改善莫西沙星使用和治愈率。

研究设计与样本

  • 回顾性分析2015-2024年墨尔本性健康中心5739例生殖支原体感染,其中2611例接受莫西沙星。
  • 疗效分析纳入1623例完成治愈检测且依从性>50%、检测前无无保护性行为的感染。

主要发现

  • 莫西沙星使用从2015年6.7%(19/282;95%CI 4.1%-10.3%)增至2023年60.3%(482/800;95%CI 56.8%-63.7%;Ptrend<.0001)。
  • 莫西沙星疗效从2015年100%(11/11)降至2023年79.3%(238/300;95%CI 74.3%-83.8%;Ptrend=.007)。
  • 引入ParC-S83检测后,2024年莫西沙星使用降至49.2%(438/890;95%CI 45.9%-52.6%;P<.0001)。
  • ParC-S83野生型感染治愈率从2023年79.3%(238/300;95%CI 74.3%-83.8%)升至2024年89.2%(116/130;95%CI 82.6%-94.0%;P=.013)。

关键数值与推荐

  • 莫西沙星疗效分析条件:完成治疗后14-90天治愈检测、报告依从性>50%、检测前无无保护性行为。
  • 2024年MSHC推荐:ParC-S83野生型感染使用莫西沙星,检出ParC-S83I突变时采用替代方案。

临床怎么用

  • 对生殖支原体感染,可考虑ParC-S83检测指导莫西沙星使用。
  • 在耐药高发区,经验性使用莫西沙星需警惕疗效下降。

局限性

  • ParC-S83检测影响为初步数据。
  • 疗效分析仅纳入符合条件者,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed trends in moxifloxacin use and efficacy for Mycoplasma genitalium over a decade at Melbourne Sexual Health Centre (MSHC). Specific M. genitalium mutations, namely ParC-S83I, have been associated with moxifloxacin failure. In 2024 MSHC introduced ParC-S83 testing, recommending moxifloxacin for ParC-S83 wild type infections and alternative regimens if the ParC-S83I mutation was detected. We present preliminary impacts of ParC-S83 testing on moxifloxacin use and efficacy. METHODS: Clients with M. genitalium from 2015 to 2024 were treated with doxycycline preceding macrolide resistance-guided azithromycin or moxifloxacin. Clients with a test of cure 14-90 days after completing moxifloxacin who reported > 50% adherence and no condomless sex prior to test of cure were eligible for efficacy analyses. Proportions with 95% CIs were calculated for moxifloxacin use and efficacy, with trends assessed by logistic regression. Moxifloxacin use and efficacy were compared in the 12 months before and after introduction of the ParC-S83 assay. RESULTS: From 2015 to 2024, 2611 of 5739 M. genitalium infections received moxifloxacin. Moxifloxacin use increased from 6.7% (n = 19/282; 95% CI, 4.1%-10.3%) in 2015 to 60.3% (n = 482/800; 95% CI, 56.8%-63.7%) in 2023 (Ptrend < .0001). Efficacy analyses included 1623 infections. Moxifloxacin efficacy decreased from 100% (n = 11/11) in 2015 to 79.3% (n = 238/300; 95% CI, 74.3%-83.8%) in 2023 (Ptrend = .007). After introduction of the ParC-S83 assay, moxifloxacin use decreased from 60.3% (n = 482/800; 95% CI, 56.8%-63.7%) in 2023 to 49.2% (n = 438/890; 95% CI, 45.9%-52.6%) in 2024 (P < .0001) and cure increased from 79.3% (n = 238/300; 95% CI, 74.3%-83.8%) in 2023 to 89.2% (n = 116/130; 95% CI, 82.6%-94.0%; P = .013) in ParC-S83 wild type infections. CONCLUSIONS: Increasing moxifloxacin use and declining efficacy reflects rising resistance in our region. Preliminary data suggest a ParC-S83 assay has the potential to improve moxifloxacin use and cure in this setting.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Matthews LG, Vodstrcil LA, Wild NL, et al. Declining Efficacy of Moxifloxacin for Mycoplasma genitalium Infection: Time for Fluoroquinolone Resistance-Guided Therapy? J Infect Dis. 2026. PMID: 42100861. doi:10.1093/infdis/jiag251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。